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SUPPLEMENTARY NOTES
ABSTRACT
The primary purpose of this research grant is to provide the necessary preclinical data demonstrating that prostate cancer cells are auxotrophic for arginine and therefore targeting arginine metabolism is a novel therapeutic approach. The primary methodology involves cell culture with the characterization of the arginine requirements for prostate cancer cell growth and then determination of the effect of arginine depletion on cell growth and cell death. Furthermore, we have investigated the mechanism of cell death and observed that arginine deprivation in those cells auxotrophic for this semi-essential amino acid induces autophagy as a precursor to programmed cell death. Major findings to date include the observation that the majority of prostate cancer cell lines lack arginine-succinate synthetase (ASS), the critical enzyme in arginine biosynthesis. Furthermore, arginine deprivation in those cell lines lacking ASS induces autophagy as a precursor to non-apoptotic cell death. Inhibition of autophagy appears to stimulate the induction of cell death. 
SUBJECT TERMS
Introduction
This is the second year of a three year grant entitled "Metabolic stress induced by arginine deprivation induces autophagy cell death in prostate cancer". The primary hypothesis of the research investigation is PEG-ADI represents a potential therapy of prostate cancer to induce metabolic stress by arginine deprivation and subsequent induction of autophagic cell death as a precursor to apoptosis in those prostate cancers lacking biosynthetic enzymes to make arginine. The specific aims to investigate this hypothesis are:
1) We will demonstrate that in those prostate cancer cells lacking ASS for which arginine is an essential amino acid, metabolic stress induced by arginine deprivation achieved by ADI-PEG treatment induces autophagic cell death as a precursor to apoptosis via a DRAMdependent pathway. From these studies, we will show: 1) ASS expression predicts cellular response to PEG-ADI, 2) PEG-ADI therapy induces arginine deprivation, 3) the consequence of the metabolic stress is the initiation of autophagosome assembly and progression to autophagic cell death, and 4) DRAM induction is required for PEG-ADI induced autophagy. 2) We will demonstrate that the induction of PEG-ADI induced autophagy in prostate cancer cells is a precursor to apoptosis; furthermore, these events sensitize cells to traditional chemotherapy-induced apoptosis. Autophagy mediators will be altered to determine effect on sensitivity to PEG-ADI induced cellular events. In addition, PEG-ADI will be combined with traditional chemotherapy to determine effect on apoptosis and in vivo tumor response.
Body
Significant progress has been accomplished during the second year of this 3-year award. The initial focus of the investigation was the characterization of the auxotrophic requirements for prostate cancer cell lines for the semi-essential amino acid arginine. These studies clearly demonstrated that only those prostate cancer cell lines lacking argininosuccinate synthetase (ASS) were sensitive to the cytotoxic effect of PEG-ADI (1). Furthermore, PEG-ADI induced autophagy as well as a caspase-independent cell death (2), though the relationship between these two cellular consequences of arginine are unclear. Therefore, the second year of the grant focused on the role of autophagy in the cell death as well as the intracellular signaling mechanisms responsible for both the induction of autophagy and cell death.
Chloroquine is a well recognized inhibitor of autophagy by blocking the final fusion of the autophagosome to the lysosome and is a common biochemical method used to inhibit autophagy. Therefore, to determine the role of autophagy in the cell death mediated by ADI, the ASS-deficient CWR22RV1 and the ASS-expressing LNCaP prostate cancer cells were treated with PEG-ADI in the absence or presence of chloroquine (ChQ). As noted previously, PEG-ADI induces cell death only in the ASS-deficient CWR22RV1 cell line but without effect on LNCaP cells (Figure, below) . However, chloroquine both accelerated the cell death and increased the cell death following PEG-ADI treatment in CWR22RV1 cells (Figure, below) , without effect on LNCaP cells. These data indicate that the autophagy initiated by PEG-ADI plays a cell survival role, inhibiting the delayed cell death. Therefore, the anticancer efficacy of PEG-ADI in prostate cancer may ultimately be increased by inhibitors of autophagy, and as chloroquine is a safe, accepted therapy in the treatment of malaria, these findings have significant impact on the further clinical development of PEG-ADI in prostate cancer. Chloroquine and ADI have no effect on LNCaP
The second direction of our research is the investigation of the signaling mechanisms that mediate the cellular events of autophagy and cell death following PEG-ADI in prostate cancer. We began by inhibition of pathways that have either been demonstrated to be important in the initiation of autophagy (e.g. AMP kinase, AKT, rag), or were observed to be activated following PEG-ADI treatment (e.g. ERK1/2, mTOR). Using either small molecule inhibitors, or siRNA-mediated knockdown, these five signaling intermediates were inhibited in to determine the effect on both induction of autophagy and cell death. Interestingly, none of the autophagy pathways (e.g. AMP kinase, AKT, rag) regulated cell death, as inhibition of each did not affect the induction of cell death mediated by PEG-ADI in CWR22RV1 cells (data not shown). Those these pathways did inhibit the induction of autophagy, as measures by immunoflourescence for LC-3, a protein involved in the assembly of the autophagosome (Figure, right) When we examined the mTOR pathway, which is activated upon treatment with PEG-ADI, we noted two key observations. First, unlike inhibition of the other pathways examined, inhibition of mTOR with rapamycin initiated autophagy. Secondly, rapamycin treatment was sufficient to induce cell death. Therefore, the cellular effects of rapamycin appeared to be similar to PEG-ADI, namely induction of autophagy and cell death. When these two treatments occurred simultaneously in CWR22RV1, the subsequent cell death was increased, with nearly additive effects ( Figure, below left panel) . These findings have led us to develop a hypothesis that while mTOR is activated by PEG-ADI, it is neither sufficient nor required for the cell death mediated by PEG-ADI (Figure below, right panel) . 
Conclusion
In our second of a three year grant entitled "Metabolic stress induced by arginine deprivation induces autophagy cell death in prostate cancer", we have made significant progress in the investigation of our central hypothesis. This has allowed us to move forward to a clinical trial of PEG-ADI in prostate cancer, which is a very noteworthy goal within 2 years of preclinical drug development. Furthermore, we have begun to elucidate signaling pathways involved in the cell death of PEG-ADI, which can be important information for additional drug development, as two of the inhibitors (chloroquine and rapamycin) are already in human use.
As far as the financial conduct of the research, we are well within the budget without any significant deviations noted or anticipated.
